1. A sustained release pharmaceutical composition for oral administration, comprising a rapid release phase and a sustained release phase, wherein said rapid release phase and a sustained release phase respectively comprise dapoxetine as an active ingredient； characterized in that dapoxetine contained in the indicated rapid release phase is eluted in an amount of 80 wt.% or more within 30 minutes, and dapoxetine contained in the indicated sustained release phase is eluted in an amount of less than 20 wt.% during the first 30 minutes 2. The pharmaceutical composition according to claim 1, characterized in that from 40 wt.% To 70 wt.% Of the total content of dapoxetine elutes during the first 30 minutes of elution. The pharmaceutical composition according to claim 1, characterized in that said rapid release phase and a sustained delayed release phase contain 20-80% by weight of dapoxetine from its total content, respectively. The pharmaceutical composition according to claim 3, characterized in that said rapid release phase and a sustained delayed release phase contain 40-60 wt.% Dapoxetine of its total content, respectively. The pharmaceutical composition according to claim 1, characterized in that said rapid release phase and a sustained delayed release phase contain 15-100 mg of dapoxetine, respectively. The pharmaceutical composition according to claim 5, characterized in that said rapid release phase and a sustained delayed release phase contain 30-60 mg of dapoxete�1. Фармацевтическая композиция с замедленным высвобождением для перорального введения, состоящая из фазы быстрого высвобождения и фазы пролонгированного замедленного высвобождения, где указанные фаза быстрого высвобождения и фаза пролонгированного замедленного высвобождения соответственно содержат дапоксетин в качестве активного ингредиента； отличающаяся тем, что дапоксетин, содержащийся в указанной фазе быстрого высвобождения, элюируется в количестве 80 масс.% или более в течение 30 минут, а дапоксет
